Quick facts about Optune
Optune is a noninvasive, portable device that is classified as durable medical equipment (DME).
Optune is a noninvasive, antimitotic cancer treatment for GBM that delivers TTFields. TTFields are electric fields that continuously and selectively disrupt cancer cell division in solid tumors.
- Watch this video to learn how TTFields work:
Transducer arrays are applied to the shaved scalp and must be changed at least 2 times per week (every 4 days, at most)
- Arrays should always have good scalp contact
- Note: Avoid activities that may result in the device or transducer arrays becoming wet. Getting the device wet may cause it damage
Recommended usage goal for Optune is 18+ hrs/day, which gives patients flexibility to decide which times of day are best for use4
Patients can benefit most from wearing Optune for the recommended time
In a phase 3 pivotal trial studying newly diagnosed GBM, 75% of patients used Optune 18 or more hours a day during the first 3 months of treatment5
- 50% daily use was the threshold for significant survival benefit over TMZ alone
- 86% of patients received a survival benefit from Optune, because they used it more than half the time (n=388/450)
Adjusting to Optune
- This brief video shows Optune users and caregivers providing their perspectives on starting to use Optune
Simple steps to start patients on Optune
Novocure® has identified a 4-step process that may help your patients with GBM start Optune and achieve their treatment goals.
GBM, glioblastoma; TMZ, temozolomide.
References: 1. Optune. Instructions for Use for Glioblastoma. Novocure; 2019. 2. China NMPA approves Optune® for the treatment of newly diagnosed and recurrent glioblastoma [press release]. St. Helier, Jersey and Shanghai: Business Wire; May 13, 2020. Accessed April 13, 2022. 3. Novocure Data on File OPT-115.3. 4. Optune. Patient Information and Operation Manual. Novocure; 2019. 5. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316.